{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:43:30Z","timestamp":1773287010504,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.canlet.2008.10.032","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T16:16:58Z","timestamp":1228493818000},"page":"61-67","source":"Crossref","is-referenced-by-count":5,"title":["Out of frame peptides from BCR\/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice"],"prefix":"10.1016","volume":"276","author":[{"given":"C.","family":"Casnici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lattuada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Crotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Panuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mastrotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.M.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Marelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2008.10.032_bib1","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2008.10.032_bib2","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr-abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2008.10.032_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2000.02090.x","article-title":"b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia","volume":"109","author":"Norbury","year":"2000","journal-title":"Br. J. Hematol."},{"key":"10.1016\/j.canlet.2008.10.032_bib4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","article-title":"A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia","volume":"103","author":"Cathcart","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2008.10.032_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observation trial","volume":"3658","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2008.10.032_bib6","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia","volume":"59","author":"Molldrem","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2008.10.032_bib7","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1158\/0008-5472.CAN-05-2868","article-title":"Bcr-Abl is not an immunodominant antigen in chronic myelogenous leukemia","volume":"66","author":"Grunebach","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2008.10.032_bib8","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/0008-5472.CAN-06-3737","article-title":"Alternative BCR\/ABL splice variants in Philadelphia chromosome positive leukemias result in novel tumor specific fusion proteins that may represent potential targets for immunotherapic approaches","volume":"67","author":"Volpe","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2008.10.032_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2008.10.032_bib10","doi-asserted-by":"crossref","first-page":"13255","DOI":"10.1073\/pnas.231326898","article-title":"Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer","volume":"98","author":"Saeterdal","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2008.10.032_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.170.4.1091","article-title":"Species-restricted interactions between CD8 and the \u03b13 domain of class I influence the magnitude of the xenogenenic response","volume":"170","author":"Irwin","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2008.10.032_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-1759(01)00499-9","article-title":"The use of HLA-A\u22170201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-gamma ELISPOT assays","volume":"259","author":"Britten","year":"2002","journal-title":"J. Immunol. Methods"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383508008574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383508008574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T04:16:50Z","timestamp":1589343410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383508008574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0304383508008574"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2008.10.032","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}